TY - JOUR
T1 - Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance
T2 - An Analysis of Post RAISE
AU - Iio, Kazuki
AU - Morikawa, Yoshihiko
AU - Miyata, Koichi
AU - Kaneko, Tetsuji
AU - Misawa, Masahiro
AU - Yamagishi, Hiroyuki
AU - Miura, Masaru
N1 - Funding Information:
Supported by grants from the Tokyo Metropolitan Government Hospitals. M.M. received an honorarium from the Japan Blood Products Organization, Teijin Pharma Ltd, and Nihon Pharmaceutical Co, Ltd. outside the submitted work. Y.M. received a Health Science and Labor Research Grant and grants from the Tokyo Metropolitan Government Hospitals, the Japan Agency for Medical Research and Development, the Center for Clinical Trials of the Japan Medical Association, the Japan Science and Technology Agency, the New Energy and Industrial Technology Development Organization, and the Japan Society for the Promotion of Science, outside the submitted work. H.Y. received research grants from Actelion Pharmaceuticals Japan Ltd and Abbvie Inc outside the submitted work. None of these entities were involved in this study in any manner. All the other authors declare no conflicts of interests.
Funding Information:
We thank James R. Valera, our in-house editor, for his help with editing and proofreading this article. Data management was provided by the Data Center at the Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center in Tokyo, Japan. We thank Yoko Saito, Kayoko Sasao, Masako Tomotsune, and Mihoko Kijima (Clinical Research Support Center at the Tokyo Metropolitan Children's Medical Center) for their invaluable assistance with data management. We thank Hiroshi Sakakibara, Takahiro Matsushima, Tsutomu Takahashi, Maki Nakazawa, Takuya Tamame, Takatoshi Tsuchihashi, Yukio Yamashita, Satoshi Takasago, Toshimasa Obonai, Michiko Chiga, Naoaki Hori, and Osamu Komiyama for their contributions to data collection. All acknowledged individuals have no industry relation, funding sources, or conflicts of interest to disclose. Funding and disclosure information is available at www.jpeds.com.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Objective: To detect risk factors of coronary artery aneurysm (CAA) development in patients with Kawasaki disease determined to have a low risk for resistance to primary intravenous immunoglobulin (IVIG) treatment based on the Kobayashi score. Study design: This study included 1757 predicted IVIG responders from Prospective Observational study on STRAtified treatment with Immunoglobulin plus Steroid Efficacy for Kawasaki disease (Post RAISE), a large-scale, multicenter, prospective cohort study of Kawasaki disease in Japan. Predicted IVIG responders were defined as patients with Kawasaki disease with a Kobayashi score of <5, a predictive scoring system for IVIG resistance created in Japan. The primary outcome was CAA development at 1 month after disease onset. CAA was defined as a Z score of ≥2.5. Multivariable logistic regression was used to identify the independent risk factors of CAA. The variables for inclusion were identified based on univariate analysis results and previously reported risk factors of CAA. Results: Among 1632 patients who had complete coronary outcome data, CAA developed in 90 patients (5.5%) at 1 month after disease onset. Multivariable analysis found that a baseline maximum Z score of >2.5, age of <12 months at fever onset, and nonresponsiveness to IVIG were significant, independent risk factors of CAA development at 1 month after disease onset. Among the risk factors, a baseline maximum Z score of >2.5 was most strongly associated with CAA development (OR, 7.1; 95% CI, 4.1-12.2; P ≤ .001). Conclusions: Predicted IVIG responders with CAA risk factors identified in this study may be candidates for future clinical trials of intensified primary IVIG treatment with prednisolone, cyclosporine or infliximab.
AB - Objective: To detect risk factors of coronary artery aneurysm (CAA) development in patients with Kawasaki disease determined to have a low risk for resistance to primary intravenous immunoglobulin (IVIG) treatment based on the Kobayashi score. Study design: This study included 1757 predicted IVIG responders from Prospective Observational study on STRAtified treatment with Immunoglobulin plus Steroid Efficacy for Kawasaki disease (Post RAISE), a large-scale, multicenter, prospective cohort study of Kawasaki disease in Japan. Predicted IVIG responders were defined as patients with Kawasaki disease with a Kobayashi score of <5, a predictive scoring system for IVIG resistance created in Japan. The primary outcome was CAA development at 1 month after disease onset. CAA was defined as a Z score of ≥2.5. Multivariable logistic regression was used to identify the independent risk factors of CAA. The variables for inclusion were identified based on univariate analysis results and previously reported risk factors of CAA. Results: Among 1632 patients who had complete coronary outcome data, CAA developed in 90 patients (5.5%) at 1 month after disease onset. Multivariable analysis found that a baseline maximum Z score of >2.5, age of <12 months at fever onset, and nonresponsiveness to IVIG were significant, independent risk factors of CAA development at 1 month after disease onset. Among the risk factors, a baseline maximum Z score of >2.5 was most strongly associated with CAA development (OR, 7.1; 95% CI, 4.1-12.2; P ≤ .001). Conclusions: Predicted IVIG responders with CAA risk factors identified in this study may be candidates for future clinical trials of intensified primary IVIG treatment with prednisolone, cyclosporine or infliximab.
KW - IVIG resistance
KW - baseline Z score
KW - predicted IVIG responder
UR - http://www.scopus.com/inward/record.url?scp=85115077825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115077825&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2021.08.065
DO - 10.1016/j.jpeds.2021.08.065
M3 - Article
C2 - 34461064
AN - SCOPUS:85115077825
SN - 0022-3476
VL - 240
SP - 158-163.e4
JO - Journal of Pediatrics
JF - Journal of Pediatrics
ER -